Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway
Source: SeekingAlpha
2025-08-11 10:01:36 ET
More on Humacyte
- Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript
- Humacyte: Revenue Ramp From Symvess Incoming
- Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey
- Humacyte GAAP EPS of -$0.24 misses by $0.08, revenue of $0.3M misses by $0.7M
- Humacyte rises on Symvess sale to military treatment facility
Read the full article on Seeking Alpha
For further details see:
Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway
Humacyte Inc. Warrant
NASDAQ: HUMAW
HUMAW Trading
10.37% G/L:
$0.1181 Last:
1,550 Volume:
$0.1087 Open:
HUMAW Latest News
HUMAW Stock Data
$247,325,345
156,832,240
N/A
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
